These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 7307426)

  • 1. Determinants of response to intravenous hydralazine in hypertension.
    Shepherd A; Lin MS; McNay J; Ludden T; Musgrave G
    Clin Pharmacol Ther; 1981 Dec; 30(6):773-81. PubMed ID: 7307426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of oral dose size on hydralazine kinetics and vasodepressor response.
    Shepherd AM; Irvine NA; Ludden TM; Lin MS; McNay JL
    Clin Pharmacol Ther; 1984 Nov; 36(5):595-600. PubMed ID: 6488679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentration and acetylator phenotype determine response to oral hydralazine.
    Shepherd AM; McNay JL; Ludden TM; Lin MS; Musgrave GE
    Hypertension; 1981; 3(5):580-5. PubMed ID: 7298112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydralazine kinetics after single and repeated oral doses.
    Shepherd AM; Ludden TM; McNay JL; Lin MS
    Clin Pharmacol Ther; 1980 Dec; 28(6):804-11. PubMed ID: 7438695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital.
    Rashid JR; Kofi-Tsepko ; Juma FD
    East Afr Med J; 1992 Jul; 69(7):406-8. PubMed ID: 1396201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Haemodynamic response to intravenous hydralazine in patients with pulmonary hypertension.
    McGoon MD; Seward JB; Vlietstra RE; Choo MH; Moyer TP; Reeder GS
    Br Heart J; 1983 Dec; 50(6):579-85. PubMed ID: 6652000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dose on acetylator phenotype distribution of hydralazine.
    Timbrell JA; Harland SJ; Facchini V
    Clin Pharmacol Ther; 1981 Mar; 29(3):337-43. PubMed ID: 7471604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic effects of intravenous hydralazine in pregnant women with severe hypertension.
    Kuzniar J; Skret A; Piela A; Szmigiel Z; Zaczek T
    Obstet Gynecol; 1985 Oct; 66(4):453-8. PubMed ID: 4047535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hypotensive response to hydralazine, in triple therapy, is not related to acetylator phenotype.
    Vandenburg MJ; Wright P; Holmes J; Rogers HJ; Ahmad RA
    Br J Clin Pharmacol; 1982 May; 13(5):747-50. PubMed ID: 7082547
    [No Abstract]   [Full Text] [Related]  

  • 11. Studies on hydralazine. III. Bioavailability of hydralazine in man.
    Talseth T
    Eur J Clin Pharmacol; 1976; 10(6):395-401. PubMed ID: 1001354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.
    Spinasse LB; Santos AR; Suffys PN; Muxfeldt ES; Salles GF
    Pharmacogenomics; 2014 Feb; 15(2):169-78. PubMed ID: 24444407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of hydralazine plasma concentration to dosage and hypotensive action.
    Zacest R; Koch-Weser J
    Clin Pharmacol Ther; 1972; 13(3):420-5. PubMed ID: 5026380
    [No Abstract]   [Full Text] [Related]  

  • 14. Hydralazine once daily in hypertension.
    Silas JH; Ramsay LE; Freestone S
    Br Med J (Clin Res Ed); 1982 May; 284(6329):1602-4. PubMed ID: 6805621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective review of the use of as-needed hydralazine and labetalol for the treatment of acute hypertension in hospitalized medicine patients.
    Gaynor MF; Wright GC; Vondracek S
    Ther Adv Cardiovasc Dis; 2018 Jan; 12(1):7-15. PubMed ID: 29265003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.
    Shen DD; Hosler JP; Schroder RL; Azarnoff DL
    J Pharmacokinet Biopharm; 1980 Feb; 8(1):53-68. PubMed ID: 7381691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylator phenotype and the antihypertensive response to hydralazine.
    Jounela AJ; Pasanen M; Mattila MJ
    Acta Med Scand; 1975 Apr; 197(4):303-6. PubMed ID: 1136859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Route and rate of hydrallazine administration as determinants to its hypotensive effect in rabbits.
    Talseth T; McNay JL; Clementi WA
    Clin Exp Pharmacol Physiol; 1980 Jul; 7(4):403-6. PubMed ID: 7418274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of hydralazine action in hypertension.
    O'Malley K; Segal JL; Israili ZH; Boles M; McNay JL; Dayton PG
    Clin Pharmacol Ther; 1975 Nov; 18(5 Pt 1):581-6. PubMed ID: 1102235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of oral hydralazine in chronic heart failure.
    Hanson A; Johansson BW; Wernersson B; Wåhlander LA
    Eur J Clin Pharmacol; 1983; 25(4):467-73. PubMed ID: 6653641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.